Zebrafish

ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS

Retrieved on: 
Tuesday, April 9, 2024

ProMIS is developing antibodies selectively targeting misfolded forms of TDP-43 and SOD1.

Key Points: 
  • ProMIS is developing antibodies selectively targeting misfolded forms of TDP-43 and SOD1.
  • ALS is a fatal neurodegenerative disease of motor neurons.
  • “Publication of these data underscores the connection of misfolded proteins and ALS and supports targeting our TDP-43-specific epitope with PMN267 as a potential therapeutic approach,” stated Neil Warma, Chief Executive Officer of ProMIS Neurosciences.
  • “PMN267 is advancing through preclinical development and is showing promise as a potential treatment for ALS.

Overeating and starving both damage the liver: Cavefish provide new insight into fatty liver disease

Retrieved on: 
Thursday, March 14, 2024

KANSAS CITY, Mo., March 14, 2024 /PRNewswire/ -- Fatty liver, which can lead to liver damage and disease, can occur from both overeating and starvation. Now, new research shows how naturally starvation-resistant cavefish, unlike other animals, are able to protect their liver and remain healthy. The findings have implications for understanding and potentially addressing liver conditions in humans.

Key Points: 
  • KANSAS CITY, Mo., March 14, 2024 /PRNewswire/ -- Fatty liver, which can lead to liver damage and disease, can occur from both overeating and starvation.
  • Now, new research shows how naturally starvation-resistant cavefish, unlike other animals, are able to protect their liver and remain healthy.
  • "We have discovered for the first time an organism – cavefish—that can avoid fatty liver under starvation conditions," said Cobham.
  • "Fatty liver can result in complications like liver cirrhosis and liver failure.

Associate Professor Ron Korstanje, Ph.D., of The Jackson Laboratory named Evnin Family Chair

Retrieved on: 
Friday, March 1, 2024

BAR HARBOR, Maine, March 1, 2024 /PRNewswire/ -- Associate Professor Ron Korstanje, Ph.D., has been named the Evnin Family Chair at The Jackson Laboratory. An expert in the genetics of kidney function and disease, Korstanje's appointment marks a new chapter in his 20 years of service to JAX's mission. 

Key Points: 
  • BAR HARBOR, Maine, March 1, 2024 /PRNewswire/ -- Associate Professor Ron Korstanje, Ph.D., has been named the Evnin Family Chair at The Jackson Laboratory.
  • "His appointment as the Evnin Family Chair bolsters our commitment to understanding the most complex health challenges of our time.
  • I'm grateful to him, and to the Evnin family for their support in helping us recruit and retain top scientists."
  • After returning to JAX in 2007 as a research scientist in Paigen's laboratory, he advanced to the rank of associate professor in 2019.

AMO Pharma Announces Collaboration with Population Health Research Institute to Advance Proof of Concept Clinical Trial to Assess Efficacy of Tideglusib in Treatment of Arrhythmogenic Cardiomyopathy

Retrieved on: 
Thursday, February 15, 2024

Enrollment is set to begin in mid-2024 at 20 sites across Canada and will include a total of 120 participants who will be randomized in a 1:1 ratio.

Key Points: 
  • Enrollment is set to begin in mid-2024 at 20 sites across Canada and will include a total of 120 participants who will be randomized in a 1:1 ratio.
  • The TaRGET trial is a critical first step in evaluating this potential."
  • This scarring increases the risk of dangerously fast heart rhythms that can lead to sudden cardiac death (SCD).
  • An implantable cardioverter defibrillator (ICD) is recommended for prevention of SCD for ACM patients considered at high risk for SCD.

AMO Pharma Announces Collaboration with Population Health Research Institute to Advance Proof of Concept Clinical Trial to Assess Efficacy of Tideglusib in Treatment of Arrhythmogenic Cardiomyopathy

Retrieved on: 
Thursday, February 15, 2024

Enrollment is set to begin in mid-2024 at 20 sites across Canada and will include a total of 120 participants who will be randomized in a 1:1 ratio.

Key Points: 
  • Enrollment is set to begin in mid-2024 at 20 sites across Canada and will include a total of 120 participants who will be randomized in a 1:1 ratio.
  • The TaRGET trial is a critical first step in evaluating this potential."
  • This scarring increases the risk of dangerously fast heart rhythms that can lead to sudden cardiac death (SCD).
  • An implantable cardioverter defibrillator (ICD) is recommended for prevention of SCD for ACM patients considered at high risk for SCD.

InVivo Biosystems Secures New Investment to Accelerate CRISPR Innovation

Retrieved on: 
Wednesday, January 3, 2024

EUGENE, Ore., Jan. 3, 2024 /PRNewswire-PRWeb/ -- InVivo Biosystems, experts in CRISPR-edited animals for biomedical discovery, today announced $3M in new investment in furtherance of the company's mission to revolutionize drug discovery leveraging its extensive intellectual property in genetically modified organisms. Rogue Venture Partners led the new investment round that included Portland Seed Fund, ONAMI, and Launch Oregon to fund further CRISPR commercialization.

Key Points: 
  • Rogue Venture Partners led the new investment round that included Portland Seed Fund, ONAMI, and Launch Oregon to fund further CRISPR commercialization.
  • "The new investment in our corporate vision at a time when CRISPR's capabilities to transform therapeutic outcomes is worldwide news, will fuel existing innovation initiatives and breakthrough capabilities," said Matt Beaudet, Chief Executive Officer, InVivo Biosystems.
  • With its CRISPR genome editing platform, InVivo Biosystems creates custom genome-edited C. elegans and zebrafish models for preclinical studies and drug discovery.
  • In addition, InVivo Biosystems provides in-vivo analytical services to produce data and insights for companies to help accelerate decision-making in the early-stage development of new compounds.

Cells Move in Groups Differently Than They Do When Alone

Retrieved on: 
Wednesday, December 13, 2023

NEW YORK, Dec. 13, 2023 /PRNewswire/ -- A protein that helps generate the force needed for single cells to move works differently in cells moving in groups, a new study shows.

Key Points: 
  • NEW YORK, Dec. 13, 2023 /PRNewswire/ -- A protein that helps generate the force needed for single cells to move works differently in cells moving in groups, a new study shows.
  • Zebrafish are a major model in the study of development because they are transparent and share cellular mechanisms with humans.
  • The current study found that the cells in the primordium instead activate RhoA in pulses in the front of the cells where it does two jobs.
  • "The machinery suggests that the movement of single cells and groups of cells is similar, but that RhoA contributes to that machinery differently in each case.

CHOP Researchers Develop Novel Method Using MRI to Study Diseases Modeled in Zebrafish

Retrieved on: 
Wednesday, September 20, 2023

PHILADELPHIA, Sept. 20, 2023 /PRNewswire/ -- Zebrafish have revolutionized research into a wide variety of rare and complex genetic diseases. In early development stages, their transparent bodies allow researchers to more easily study tissues and organs. However, studying organ-level defects in adult zebrafish presents a variety of challenges that prevent researchers from studying them at a microscopic level.

Key Points: 
  • In a new study, researchers from Children's Hospital of Philadelphia (CHOP) have developed a noninvasive method for conducting magnetic resonance imaging (MRI) in adult zebrafish.
  • In addition, zebrafish are often used to create models to study diseases because zebrafish share about 70% of genes found in humans.
  • While MRI has been used to study zebrafish, prior studies have been very limited and did not provide systematic organ-level analyses.
  • Zebrafish.

Why Japan has started pumping water from Fukushima into the Pacific – and should we be concerned?

Retrieved on: 
Friday, August 25, 2023

Japan’s decision to release water from the Fukushima nuclear power plant has been greeted with horror by the local fishing industry as well as China and several Pacific Island states.

Key Points: 
  • Japan’s decision to release water from the Fukushima nuclear power plant has been greeted with horror by the local fishing industry as well as China and several Pacific Island states.
  • China – which together with Hong Kong imports more than US$1.1bn (£866m) of seafood from Japan every year – has slapped a ban on all seafood imports from Japan, citing health concerns.
  • Japan remains steadfast in its assurance that the water is safe.

Contaminated water

    • Since the accident, water has been used to cool the damaged reactors.
    • But, as the reactor core contains numerous radioactive elements, including ruthenium, uranium, plutonium, strontium, caesium and tritium, the cooling water has become contaminated.
    • Tritium is a radioactive form of hydrogen that forms water molecules with properties similar to regular water.
    • To safely store the water that will continue to be contaminated over that time (some 100 tonnes of water each day), the plant’s operators will need to construct an additional 2,700 storage tanks.

Should we be concerned?

    • However, much of this research has focused on organisms such as zebrafish and marine mussels.
    • Interestingly, the zebrafish were exposed to tritium concentrations similar to those estimated to be in the storage tanks at Fukushima.
    • Marine organisms within the discharge zone will experience consistent exposure to this low concentration over the next 30 years.

But that’s not everything

    • The amount of tritium used in this study was over 3,000 times less than that used in the French study.
    • But it still exceeded the levels being discharged into the Pacific Ocean from Fukushima by almost 250 times.

Zebrafish are a scientist's favorite for early-stage research – especially to study human blood disorders

Retrieved on: 
Monday, August 7, 2023

But not just any organism can adequately model how human cells behave.

Key Points: 
  • But not just any organism can adequately model how human cells behave.
  • In the Espín Lab at Iowa State University, we study the early stages of blood development, particularly the birth of blood stem cells, which happens only once during embryonic development.
  • Although we want to understand how these genes work in the context of human blood development, testing on human embryos is obviously ethically impossible.

Zebrafish as a model organism

    • Zebrafish have several traits that make them excellent model organisms.
    • One day of development in zebrafish is equivalent to approximately 90 days of human development.
    • Approximately 70% of zebrafish genes have similar analogs in people, allowing researchers to study how certain genes work.

Studying blood disorders with zebrafish

    • Beyond sharing a significant percentage of genes with people, zebrafish are especially useful to blood development research because they produce the same types of blood cells.
    • Mature blood cells are derived from blood stem cells.
    • Therefore, studying how these stem cells are made would aid in developing treatment for numerous blood disorders that rely on blood stem cell therapies, such as leukemia, lymphoma and anemia.
    • Labs like ours use zebrafish to study how specific cell signaling pathways contribute to the birth, development and maturation of these blood stem cells.